Full Dose Paclitaxel Plus Vinorelbine as Salvage Chemotherapy in Anthracycline-Resistant Advanced Breast Cancer: A Phase II Study

REFERENCES

• Fossati R, Confalonieri C, Torn E, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31510 women. J Clin Oncol 1998; 16: 3439-3460.
   Google Scholar
• Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974–984.
   PubMed Web of Science ®Google Scholar
• French Epirubicin Group. A prospective randomized phase III trial combination chemotherapy with cyclophospha-mide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679–688.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Asmar L, Hortobagyi GN. Impact of patient characteristics on treatment outcome: Anthracycline resistan-ce. Eur J Cancer 1997; 33: S3-S6 (suppl 7).
   Google Scholar
• Porkka K, Blomqvist C, Rissamen P, et al. Salvage the-rapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for advan-ced breast cancer. J Clin Oncol 1994; 12: 1639–1647.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–1805.
   PubMed Web of Science ®Google Scholar
• Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimula-ting factor as initial chemotherapy for metastatic breast can-cer. J Clin Oncol 1993; 11: 1943–1951.
   PubMed Web of Science ®Google Scholar
• Wiserman L, Spencer CM. Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 1998; 12: 305–334.
   PubMed Web of Science ®Google Scholar
• Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by three-hour infusion as initial and salvage che-motherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575–2581.
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245–1252.
   PubMed Web of Science ®Google Scholar
• Smith GA. Current status of vinorelbine for breast can-cer. Oncology 1995; 9: 767–773.
   PubMedGoogle Scholar
• Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 1994; 12: 2094–2101.
   PubMed Web of Science ®Google Scholar
• Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: An active non cross resistant drug in advanced breast cancer-Results from a phase II study. Breast Cancer Res Treat 1996; 39: 285–291.
   PubMed Web of Science ®Google Scholar
• Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensi-ve vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395–1400.
   PubMed Web of Science ®Google Scholar
• Photiou A, Shah P, Leong LK, et al. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 1997; 33 : 463–470.
   PubMed Web of Science ®Google Scholar
• Culine S, Roch I, Pinguet F. Combination paclitaxel and vinorelbine therapy : In vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int J Oncol 1999; 14: 999–1006.
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Hortobagyi GN, Valero V, et al. Phase I study of vinorelbine and paclitaxel by simultaneous three-hour infusion for untreated metastatic breast cancer. Proc Am Assoc Cancer Res 1995; 36: 1443 (abstr).
   Google Scholar
• Hortobagyi GN, Ibrahim N. Paclitaxel-containing combi-nation chemotherapy for metastatic breast cancer. Semin Oncol 1996; 23 (Suppl. 1): 53-57.
   Google Scholar
• Michelotti A, Gennari A, Salvadori B, et al. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study. Ann Oncol 1996; 7: 857–860.
   PubMed Web of Science ®Google Scholar
• Tortiorello A, Facchini G, Caponigro F, et al. Phase I-II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998; 47: 91–97.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.
   PubMedGoogle Scholar
• Gardin G, Pronzato P, Tognoni A, et al. A phase II trial of vinorelbine and paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline containing chemotherapy. Proc Am Soc Clin Oncol 1998; 17: 542 (abstr).
   Google Scholar
• Romero Acuna L, Langhi M, Perez J, et al. Vinorelbine and paclitaxel as first-line chemotherapy in meta-static breast cancer. J Clin Oncol 1999; 17: 74–81.
   PubMed Web of Science ®Google Scholar
• Cocconi G, Mambrini A, Vasini G, et al. Vinorelbine combined with paclitaxel, administered in a continuous 96-hour i.v. infusion in pretreated advanced breast cancer patients. Proc Am Soc Clin Oncol 1998; 17: 800 (abstr).
   Google Scholar
• Ellis GK, Gralow JR, Pierce HI, et al. Infusional pacli-taxel and weekly vinorelbine chemotherapy with concurrent fil-gastrim for metastatic breast cancer: High complete response rate in a phase I-II study of doxorubicin-treated patients. J Clin Oncol 1999; 17: 1407–1412.
   PubMed Web of Science ®Google Scholar
• Martin M, Lluch A, Casado A, et al. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 2000; 11: 85–89.
   PubMed Web of Science ®Google Scholar
• Vici AP, Amodio A, Di Lauro L, et al. First-line che-motherapy with Vinorelbine and Paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 2000; 58: 3–7.
   PubMed Web of Science ®Google Scholar
• Di Paola R, Rodriguez R, Recio A, et al. Amifostine and dose intense paclitaxel in patients with advanced mali-gnancies. Cancer Ther 1998; 1: 11–17.
   Google Scholar
• Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without Amifostine in patients with metastatic breast cancer. J Clin Oncol 1999 ; 17: 3038–3047.
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitu-mor efficacy and cardiac effects in a dose-finding and sequen-ce-finding study. J Clin Oncol 1995; 13: 2688–2699.
   Google Scholar